Lupus News and Research

Latest Lupus News and Research

Mycophenolate mofetil is effective for managing symptoms of the most common type of lupus

Mayo Clinic investigators have found that the medication mycophenolate mofetil is effective for managing symptoms of systemic lupus erythematosus (SLE), the most common type of lupus, for patients whose SLE does not affect the kidneys.

18 Oct 2004

Biomedical engineers receive $11.5 million to study how white blood cells navigate

We all know the power of touch: A whack on the skull – or a hug – can convey more information than other forms of communication ever can. It turns out the same is true inside our bodies

12 Oct 2004

Signaling pathway could be a valuable target for future drug therapies against systemic lupus erythematosus

Medical investigators at the Hospital for Special Surgery have identified an important new signaling pathway they believe could be a valuable target for scientists to aim at with future drug therapies that might one day reverse diseases such as systemic lupus erythematosus, according to a recent article published in “Nature Immunology.”

11 Oct 2004

Shortage of pediatric rheumatologists often leads to improper diagnosis and treatment

More than 150,000 children in the United States are affected by rheumatic diseases such as juvenile rheumatoid arthritis, lupus, dermatomyositis, scleroderma, and systemic vasculitis.

10 Oct 2004

Study on the long-term health effects associated with silicone breast implants

It is estimated that between 1.5 million and 2 million women in this country have had breast implants since they first appeared on the market in 1962.

23 Sep 2004

Important that nurses help women find ways to bond with their infants when breast-feeding is not possible

New mothers with fibromyalgia (FM) face multiple barriers to breast-feeding their babies, according to a study published recently in the American Journal of Maternal/Child Nursing.

20 Sep 2004

Cancer drug effective at treating lupus

A drug now used to treat a type of cancer appears to be very effective at treating lupus, with just one injection easing symptoms in several patients for a year or more.

16 Sep 2004

Cancer drug may reduce kidney disease in lupus

A drug that is already being tested as an anticancer agent, especially in lymphoma, may also reduce the kidney disease that is a result of systemic lupus, according to a researcher at Wake Forest University Baptist Medical Center.

10 Sep 2004

Novel disease mechanism underlying rheumatoid arthritis

Investigators at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) have identified a novel disease mechanism underlying rheumatoid arthritis that may open the door to new therapies for this and other debilitating autoimmune disorders.

23 Aug 2004

Researchers find important gene for lupus

Researchers at the University of Minnesota have identified, for the first time, a gene variation associated with systemic lupus erythematosus (SLE), a potentially fatal disease which causes the body's defence system to attack itself.

18 Aug 2004

Genetic mutation is a major contributor to type 1 diabetes

A natural mutation of a gene that helps regulate the reactivity of the immune system is a major contributor to type 1 diabetes, Medical College of Georgia researchers have found.

12 Jul 2004

Relatively little is known about Lupus

Doctors have today launched an appeal for volunteers to take part in a new study into the widespread, yet largely unknown, autoimmune disease, SLE or Lupus.

1 Jul 2004

Mysterious disease that causes the body’s immune system to turn against itself

A mysterious disease that causes the body’s immune system to turn against itself also sends a warning signal to alert doctors of the onset of its worst symptoms, University of Florida physicians have found.

25 Jun 2004

Genetic variation that doubles the risk for rheumatoid arthritis

A team of researchers has discovered a genetic variation that doubles the risk for rheumatoid arthritis (RA).

24 Jun 2004

Results from study of Rituxan in rheumatoid arthritis show promise

Genentech, Inc., Biogen Idec and Roche have announced that the New England Journal of Medicine published the results of a Phase IIa study showing that two doses of Rituxan® (Rituximab), administered two weeks apart, improved symptoms in patients with moderate-to-severe rheumatoid arthritis (RA) for up to 48 weeks when combined with methotrexate (MTX), compared to MTX alone.

16 Jun 2004